Live Breaking News & Updates on Primary Analysis Results From

Stay updated with breaking news from Primary analysis results from. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

Michael Wang, MD, presents the primary analysis results from the multinational, randomized, double-blind, phase 3 SYMPATICO study comparing ibrutinib plus venetoclax vs ibrutinib plus placebo in patients with relapsed/refractory mantle cell lymphoma (R/R MCL). ....

Ibrutinib Combined With Venetoclax , Patients With , Refractory Mantle Cell Lymphoma , Primary Analysis Results From , Randomized Phase , Mantle Cell Lymphoma , Rr Mcl , Relapsed Refractory Mantle Cell Lymphoma ,